These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9187843)

  • 1. Low-dose danazol in the treatment of livedoid vasculitis.
    Hsiao GH; Chiu HC
    Dermatology; 1997; 194(3):251-5. PubMed ID: 9187843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Livedoid vasculitis. Response to low-dose danazol.
    Hsiao GH; Chiu HC
    Arch Dermatol; 1996 Jul; 132(7):749-51. PubMed ID: 8678566
    [No Abstract]   [Full Text] [Related]  

  • 3. Livedoid vasculitis with anticardiolipin antibodies: improvement with danazol.
    Wakelin SH; Ellis JP; Black MM
    Br J Dermatol; 1998 Nov; 139(5):935-7. PubMed ID: 9892980
    [No Abstract]   [Full Text] [Related]  

  • 4. Livedoid vasculitis responding to PUVA therapy.
    Lee JH; Choi HJ; Kim SM; Hann SK; Park YK
    Int J Dermatol; 2001 Feb; 40(2):153-7. PubMed ID: 11328402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
    Collatos C; Barton MH; Prasse KW; Moore JN
    J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Univariate tolerance regions for fibrinogen, antithrombin III, protein C, protein S, plasminogen and alpha 2-antiplasmin in children using the new Automated Coagulation Laboratory (ACL) method.
    Nowak-Göttl U; Funk M; Mosch G; Wegerich B; Kornhuber B; Breddin HK
    Klin Padiatr; 1994; 206(6):437-9. PubMed ID: 7529848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant elevation of protein C and protein S levels in thrombotic disorders by low dose danazol.
    al-Momen AK; Gader AM; Shamena AR; Daif AK; Ajarim D
    Blood Coagul Fibrinolysis; 1991 Aug; 2(4):495-9. PubMed ID: 1837483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator for treatment of livedoid vasculitis.
    Klein KL; Pittelkow MR
    Mayo Clin Proc; 1992 Oct; 67(10):923-33. PubMed ID: 1434852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis.
    Swiatkiewicz A; Jurkowski P; Kotschy M; Ciecierski M; Jawień A
    Med Sci Monit; 2002 Apr; 8(4):CR263-8. PubMed ID: 11951068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
    Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Livedoid vasculopathy and high levels of lipoprotein (a): response to danazol.
    Criado PR; de Souza EspinelI DP; Valentef NS; Alavi A; Kirsner RS
    Dermatol Ther; 2015; 28(4):248-53. PubMed ID: 25824252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis.
    Vaziri ND; Gonzales EC; Wang J; Said S
    Am J Kidney Dis; 1994 Jun; 23(6):828-35. PubMed ID: 8203365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.
    Petăjă J; Peltola K; Sairanen H; Leijala M; Kekomäki R; Vahtera E; Siimes MA
    J Thorac Cardiovasc Surg; 1996 Sep; 112(3):665-71. PubMed ID: 8800154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of exploratory laparotomy on plasma and peritoneal coagulation/fibrinolysis in horses.
    Baxter GM; Parks AH; Prasse KW
    Am J Vet Res; 1991 Jul; 52(7):1121-7. PubMed ID: 1892267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
    Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
    Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
    Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
    Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose danazol for vascular access and dialyzer thrombosis in hemodialysis patients.
    al-Momen AK; Huraib SO
    Haemostasis; 1992; 22(1):12-6. PubMed ID: 1521823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic efficacy of six plasma proteins in evaluating consumptive coagulopathies. Use of receiver operating characteristic curves to compare antithrombin III, plasminogen, alpha 2-plasmin inhibitor, fibronectin, prothrombin, and protein C.
    Cembrowski GS; Griffin JH; Mosher DF
    Arch Intern Med; 1986 Oct; 146(10):1997-2002. PubMed ID: 3767544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of low-dose oral contraceptives on coagulation and fibrinolysis in two high-risk populations: young female smokers and older premenopausal women.
    Notelovitz M; Levenson I; McKenzie L; Lane D; Kitchens CS
    Am J Obstet Gynecol; 1985 Aug; 152(8):995-1000. PubMed ID: 4025463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.
    Rodzynek JJ; Urbain D; Leautaud P; Wettendorff P; Delcourt A
    Gut; 1984 Oct; 25(10):1050-6. PubMed ID: 6479679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.